Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 8974 results

  1. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTE10079 Expected publication date:  04 February 2027

    Health technology evaluations
    In development

  2. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    In development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  4. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  5. Norucholic acid for treating primary sclerosing cholangitis [ID6583]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 8 April 2026.

    Technology appraisal guidance
    In consultation

  6. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTE10084 Expected publication date:  21 October 2026

    Health technology evaluations
    In development

  7. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  02 December 2026

    NICE guideline
    In development

  8. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  9. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  12. Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

    Awaiting development Reference number: GID-TA11828 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date:  15 October 2026

    Interventional procedures guidance
    In development

  14. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development Reference number: GID-TA10431 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development